| Dr Girish Kotreshwar Hiremath, MD | |
|
931 Chatham Ln, Columbus, OH 43221-2417 | |
| (614) 533-5500 | |
| (614) 533-5593 |
| Full Name | Dr Girish Kotreshwar Hiremath |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 22 Years |
| Location | 931 Chatham Ln, Columbus, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811163603 | NPI | - | NPPES |
| 3082711 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 35.087904 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Dublin Methodist Hospital | Dublin, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ohiohealth Corporation | 6305758426 | 1900 |
News Archive
Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.
Growing evidence suggests that Parkinson's disease (PD) often starts with non-motor symptoms that precede diagnosis by several years. In the first study to examine patterns in the quality of life of Parkinson' disease patients prior to diagnosis, researchers have documented declines in physical and mental health, pain, and emotional health beginning several years before the onset of the disease and continuing thereafter.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.
In a new pre-clinical study published this week in the journal Leukemia, the research team of Children's Hospital Los Angeles investigator Hisham Abdel-Azim, MD, MS, worked with colleagues to engineer T-cells to identify and target multiple sites on acute lymphoblastic leukemia cells instead of just one. The early collaboration points the way to future clinical trials to test the therapy.
4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany.
› Verified 8 days ago
| Entity Name | Ohiohealth Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.
Growing evidence suggests that Parkinson's disease (PD) often starts with non-motor symptoms that precede diagnosis by several years. In the first study to examine patterns in the quality of life of Parkinson' disease patients prior to diagnosis, researchers have documented declines in physical and mental health, pain, and emotional health beginning several years before the onset of the disease and continuing thereafter.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.
In a new pre-clinical study published this week in the journal Leukemia, the research team of Children's Hospital Los Angeles investigator Hisham Abdel-Azim, MD, MS, worked with colleagues to engineer T-cells to identify and target multiple sites on acute lymphoblastic leukemia cells instead of just one. The early collaboration points the way to future clinical trials to test the therapy.
4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Girish Kotreshwar Hiremath, MD 5350 Frantz Rd, Dublin, OH 43016-4259 Ph: () - | Dr Girish Kotreshwar Hiremath, MD 931 Chatham Ln, Columbus, OH 43221-2417 Ph: (614) 533-5500 |
News Archive
Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.
Growing evidence suggests that Parkinson's disease (PD) often starts with non-motor symptoms that precede diagnosis by several years. In the first study to examine patterns in the quality of life of Parkinson' disease patients prior to diagnosis, researchers have documented declines in physical and mental health, pain, and emotional health beginning several years before the onset of the disease and continuing thereafter.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.
In a new pre-clinical study published this week in the journal Leukemia, the research team of Children's Hospital Los Angeles investigator Hisham Abdel-Azim, MD, MS, worked with colleagues to engineer T-cells to identify and target multiple sites on acute lymphoblastic leukemia cells instead of just one. The early collaboration points the way to future clinical trials to test the therapy.
4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany.
› Verified 8 days ago
Dr. Mynor Mendez Valdez, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 300 W 10th Ave Fl 12, Columbus, OH 43210 Phone: 440-975-6868 | |
Douglas A. Hardesty, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-8714 Fax: 614-293-4281 | |
Michael J Meagher, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 931 Chatham Ln, Columbus, OH 43221 Phone: 614-533-5500 Fax: 614-533-5593 | |
Sigurdur A Stephensen, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 931 Chatham Ln, Columbus, OH 43221 Phone: 614-457-4880 Fax: 614-457-4890 | |
Dr. Vikram Badhri Chakravarthy, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 300 W 10th Ave, Columbus, OH 43210 Phone: 614-293-8714 Fax: 614-293-4281 | |
Dr. Andrew James Grossbach, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 543 Taylor Ave, Columbus, OH 43203 Phone: 614-293-8714 Fax: 614-293-4281 | |
Dr. Gregory W. Balturshot, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3525 Olentangy River Rd, Suite 5310, Columbus, OH 43214 Phone: 614-261-0073 Fax: 614-268-5611 |